When two specialist healthcare funds square off on the same stock, the market tends to take notice.
Fresh off the latest 13F filings, a clear divergence has emerged: Logos Global Management aggressively piled into Immunovant (NASDAQ: IMVT) during the fourth quarter, while Alpine Global Management quietly trimmed its position. The contrasting moves raise a critical question for investors: Is this a moment to follow the money, or a signal to head for the exits?
San Francisco-based Logos, known for its concentrated, research-driven approach to biotech, purchased 1.1 million shares of Immunovant in Q4. The transaction is valued at an estimated $24.5 million based on average quarterly pricing.
While the dollar amount is substantial, the portfolio shift tells a more compelling story. Before the purchase, Immunovant represented just 0.4% of Logos’s 13F assets. After the buy, that weighting jumped to 2.11%. For a fund that builds its strategy around deep scientific and regulatory diligence, this level of conviction signals a clear view: Logos believes Immunovant’s risk-reward profile has shifted enough to warrant a significant position.
By quarter’s end, Logos held 1.375 million shares, valued at approximately $35 million.
Alpine’s move tells a different—but not necessarily contradictory—story. The fund sold 128,039 shares during the same period, a transaction worth an estimated $2.8 million. Crucially, this was not an exit. Immunovant remains Alpine’s largest holding, accounting for a commanding 11.36% of its reported 13F assets, with a quarter-end value of $66.8 million on 2.63 million shares.
The reduction looks more like routine portfolio management than a crisis of confidence. Immunovant shares climbed more than 29% over the past year, handily beating the S&P 500. After a run like that, trimming a position that still accounts for more than 11% of assets is a standard move to lock in gains and manage concentration risk. Alpine’s long-term thesis, it appears, remains intact.
Despite their divergent trading strategies, both funds are ultimately focused on the same thing: Immunovant’s pipeline.
The company is a clinical-stage biopharmaceutical firm built around batoclimab, an anti-FcRn antibody targeting autoimmune diseases like myasthenia gravis and thyroid eye disease (TED). Immunovant has no approved products and generates no revenue. Its entire valuation hinges on clinical milestones.
The next major catalyst is looming. Topline data from two parallel Phase 3 trials evaluating batoclimab for thyroid eye disease are expected in the first half of 2026. For a clinical-stage biotech, Phase 3 data is the finish line—or the end of the road. Success opens the door to regulatory approval and commercialization; failure could wipe out years of development.
Logos is placing a heavy bet on success, building a position ahead of the readout. Alpine’s trim can be seen as a hedge against the binary risk inherent in that very same event.
For individual investors, the moves by Logos and Alpine offer a useful lens—but not a trading signal.
Logos’s purchase reflects a conviction born of proprietary research: that the probability of success for batoclimab, and the market’s underestimation of it, justifies a significant allocation. But conviction is not data. Alpine’s sale is a reminder that even with a bullish long-term view, professional money managers de-risk ahead of binary events—especially after a 30% run-up in the stock.
The fundamental reality of Immunovant hasn’t changed. It remains a pre-commercial biotech with no revenue, significant losses, and a market cap entirely dependent on clinical outcomes. The only thing that will ultimately matter is the data.
For investors trying to decide which fund to follow, the answer may be to follow neither—and instead focus on the same catalyst the professionals are watching. The batoclimab Phase 3 readout in the first half of 2026 will settle the debate. Until then, every buy or sell decision is simply a wager on uncertainty.
